Trials / Completed
CompletedNCT00193297
Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma
A Phase II Study of a Three-Day Schedule of Topotecan Plus Paclitaxel and Carboplatin on Day Three in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (planned)
- Sponsor
- SCRI Development Innovations, LLC · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the feasibility and toxicity of the combination of paclitaxel, carboplatin, and topotecan in patients with previously untreated, stage III or IV epithelial ovarian carcinoma or primary peritoneal carcinoma. We will also make a preliminary evaluation of the efficacy of this three drug regimen in the initial treatment of these patients.
Detailed description
Upon determination of eligibility, all patients will be receive: Paclitaxel + Carboplatin + Topotecan a maximum of six courses of chemotherapy will be given at 21 day intervals
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Topotecan | |
| DRUG | Paclitaxel | |
| DRUG | Carboplatin |
Timeline
- Start date
- 2002-02-01
- Primary completion
- 2005-06-01
- Completion
- 2006-06-01
- First posted
- 2005-09-19
- Last updated
- 2011-05-03
Source: ClinicalTrials.gov record NCT00193297. Inclusion in this directory is not an endorsement.